{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6K2IkJDA","lastupdate":"2022-10-21T00:00:00.000Z","update_date":"2022-10-21T00:00:00.000Z","lastModified":"Mar 3, 2026","active":1,"confidence_score":76,"confidence_score_reason":"tags, homepage, funding rounds, markets, not claimed","urlname":"micromedic","minimal_profile":null,"status":"Public","fullstatus":"Public on TASE on May 1993;","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$6gCLHFXDFnKOcxSO98mGVlyq7Fm0EYizrAe5OnYzcblGQEetk80kys.png","name":"Nextage Therapeutics","oneliner":"A pioneer in targeted nano-liposomes based drug delivery across the Blood-Brain-Barrier","registrar":"520039181","website":"","careerspage":"","founded_month":3,"founded_year":2006,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/nextage-tx/","instagram":""},"social":["https://www.linkedin.com/company/nextage-tx/"],"flattenedsociallinks":"https://www.linkedin.com/company/nextage-tx/","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":15,"patent":1,"raised":0,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Nextage Therapeutics (TASE: NXTG) is a pioneer in targeted nano-liposomes based drug delivery across the blood-brain-barrier. The company has developed a proprietary BTLs drug delivery platform which is being studied for various therapeutic applications, and its lead drug candidate is currently under development for treatment of glioblastoma.  \n\nThrough its subsidiary Nextar Chempharma Solutions, Israel's leading CDMO with 20 years cGMP and ISO 13485 compliant track record, the company also provides development and commercial manufacturing services for pharmaceuticals and medical devices across a broad range of technologies and dosage forms including drug substance synthesis, formulation development, scale up and sterile manufacturing, from preclinical development through clinical trials and commercial supply.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+972732244440","country":null,"address":{"israeli":[{"id":"5c3bd358-6fa7-486a-89ea-7c40a47a7db2","city":"Ness Ziona","type":null,"address":" Einstein St 13, Ness Ziona, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"tVHrOlbFGmR16dZZII2w4Mi5O2nsHtlsstELJPQAa5Sk7cf1Ywlq5F","date":"Mar 3, 2026","link":"https://www.linkedin.com/posts/nextage-tx_tel-aviv-march-3-2026-nextage-therapeutics-activity-7434542257355186177-FVu7?utm_source=share&utm_medium=member_desktop&rcm=ACoAAABTirIBzTFg-yo1RkMLtlE8anLInwNBDfI","source":"www.linkedin.com","visible":1,"analysis":{"tags":"patent","round":null,"company":"Nextage Therapeutics","layoffs":null,"summary":"Nextage Therapeutics has secured a European patent for its innovative nano-liposome platform, which is designed for targeted drug delivery across the Blood-Brain-Barrier. This patent, granted by the European Patent Office, enhances the companys intellectual property portfolio and commercial readiness, accelerating its path toward clinical development. The patent is part of a global strategy to protect intellectual property in major pharmaceutical markets, including the United States and China. The achievement is seen as a strategic milestone that strengthens Nextages position in the market and supports future technological innovation and pipeline expansion.","partners":"Technion, Israel Institute of Technology","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["patent","technology","innovation","intellectual property","drug delivery"],"date_of_event":"March 3, 2026","product_stage":"R&D","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1NwlCPdM3nwu3gYWz9yOA2o6AyBPQ6xHpfDFABS1LKA0kBgW0CJVi3","news_summary":"Nextage Therapeutics Secures European Patent for Its Breakthrough Nano-Liposome Platform.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"LoRHhoXjeuIfEkKWLfT9egPmXgCfu1UG2FAhOjUTsIsxzlWDHOixaO","date":"Feb 8, 2026","link":"https://www.funder.co.il/article/195348","source":"www.funder.co.il","visible":1,"analysis":null,"sentiment":null,"analysisId":"oj7LmqD88FdbKHFLcXG31sLTaIE0tNivVeusZ9QI4Qr35t6pqqTdv6","news_summary":"נקסטייג׳ תראפיוטיקס מודיעה על מינוי אילן אבני למנכ\"ל החברה","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"7ZjlNOmkmMwUtDaTM8Z5YXjBqlzgMPe28F1XNH34MPP6ZNsApOped1","date":"Sep 18, 2023","link":"https://www.sponser.co.il/Article.aspx?_atscid=7_134353_204082920_2472797_0_Txtetaxjxdshwhus8sp&ArticleId=113102","source":"www.sponser.co.il","visible":1,"analysis":{"tags":"merger, stock exchange","company":"Nextage","layoffs":"N/A","summary":"Nextage, a company that develops psychedelic-based drugs to treat brain diseases and chronic pain, has announced a merger with Nextr. The merger will be conducted through a stock exchange, with Nextr shareholders owning approximately 74.99% of Nextage. The merger is expected to significantly increase Nextages revenue and add a significant technological pipeline, particularly in the field of brain research. Nextr is a private company that has been providing chemical development and manufacturing services for drugs and medical devices for 15 years.","partners":"Nextr","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["merger","stock exchange","revenue growth","pharmaceutical development","investment"],"date_of_event":"18/09/2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Acquisition","acquisition_amount":"N/A","structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"NqqCfyUQTVCv4WS68PfQpVGDDjIrFActD9J5Uui9SM81c1HMO9axSm","news_summary":"נקסטייג’ חתמה על הסכם למיזוג נקסטר לפי שווי של לא פחות מ-78 מיליון שקל","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9b957cea-4a74-4348-b5fd-2c9dac0cfdc7","date":"Aug 17, 2021","link":"https://www.jpost.com/health-science/israeli-team-aims-to-treat-neurological-disorders-with-psychedelics-676923","source":"www.jpost.com","visible":1,"analysis":{"tags":"psychedelic therapy","company":"Nextage Therapeutics","layoffs":null,"summary":"Nextage Therapeutics, an Israeli company, has developed a technology to optimize the use of psychedelic molecules for the treatment of neurological disorders. The company has signed an agreement with MindMend to use its delivery technology for drug products based on noribogaine. Nextage aims to reduce the side effects of drugs by improving their delivery to the brain through the blood-brain barrier. The company has completed preclinical work and is planning a Phase I/II clinical trial for the use of CBD. Nextage is part of a group that has been in the drug delivery business for 14 years and recently completed a $2 million funding round. The company is committed to spearheading the emerging psychedelic therapy industry in Israel.","partners":["MindMend"],"customers":null,"investors":null,"confidence":9,"key_topics":["Neurological disorders","Psychedelic therapy","Drug development","Blood-brain barrier","Nextage Therapeutics"],"date_of_event":"2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$2 million","structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"t6bLLh8Vd59p585jsTuHEg9N9b9MArQUDl1ff57ilEVITjkvfdECiF","news_summary":"https://www.jpost.com/health-science/israeli-team-aims-to-treat-neurological-disorders-with-psychedelics-676923","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"eb4d47a6-2122-42f4-8d6b-feb553472abc","date":"Jul 13, 2021","link":"https://www.sponser.co.il/Article.aspx?_atscid=7_134353_204082920_1921813_0_Txtetaxjxdshwhus8sp&ArticleId=105575&from=hp","source":"www.sponser.co.il","visible":1,"analysis":{"tags":"Product Development, Safety Trial","company":"נקסטייג’","layoffs":"Not mentioned","summary":"Israeli company Nextage has reported the completion of a safety trial related to the development of a platform for the direct and targeted delivery of active substances including cannabinoids and other psychedelic substances to the brain. The trial found the platform to be safe and no acute toxicity of the BTLS technology was observed. The company believes the completion of the safety and toxicity trial is a milestone in the development of new products for the treatment of brain and nervous system diseases based on the technology in combination with cannabinoids or psychedelic substances.","partners":"Mind Medicine","customers":"Not mentioned","investors":"Not mentioned","confidence":7,"key_topics":"Safety Trial, Product Development, Cannabis, Psychedelics","date_of_event":"Not mentioned","valuation_amount":"132 million NIS","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qEWslBJwES4DEDczI3G3pqSqcWJh7v9j1uKZYC1TRMgTfdpo7lnl1e","news_summary":"נקסטייג' מציגה תוצאות חיוביות בניסוי בטיחות, המניה מזנקת","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d995d982-b7d5-49cc-98c3-ed1d15c029d2","date":"Jun 27, 2021","link":"https://www.sponser.co.il/Article.aspx?_atscid=7_134353_204082920_1901007_0_Txtetaxjxdshwhus8sp&ArticleId=105365","source":"www.sponser.co.il","visible":1,"analysis":{"tags":"CBD, sales, expansion","company":"נקסטייג","layoffs":null,"summary":"Nextage, a research and development company specializing in cannabis and psychedelic-based products, has announced the start of sales of CBD-integrated products in the Canadian market. The company has received approval from the Canadian Ministry of Health. The initial orders amount to tens of thousands of Canadian dollars and were made from two provinces in Canada. Nextage aims to expand distribution to additional provinces and register more products. The products are sold under the brand Nuveev, a Canadian company jointly owned by Nextage and Cannovate Holdings Inc. Nextage sees the purchase orders as a significant event, as Canada is a strategic territory for the companys business strategy in CBD and wellness product development and trading.","partners":"Cannovate Holdings Inc.","customers":null,"investors":null,"confidence":8,"key_topics":["CBD","sales","expansion","partnerships","product development"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"VowfAe4aa3RcQyzhCzqfgM9t9vuI57uj8bBsLxgI4xjqBYRcVIw9at","news_summary":"נקסטייג' מתחילה למכור מוצרי CBD בקנדה","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"23b10a58-d2c6-488c-9dd1-9f5d00a3eb47","date":"May 24, 2021","link":"https://www.prnewswire.com/news-releases/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system-301297517.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":["collaborative development program","psychedelic medicine","drug delivery technology"],"company":"MindMed","layoffs":null,"summary":"MindMed and Nextage Therapeutics have announced a collaborative development program to optimize the delivery of certain psychedelic drug candidates. They will leverage Nextages proprietary Brain Targeting Liposome System (BTLS) delivery technology to develop drug products based on noribogaine and other ibogaine derivatives. The collaboration aims to reduce the serious side effects of orally administered psychedelics and improve the risk-benefit profile of their delivery. The parties will share development costs and intellectual property arising from the collaboration. The companies will pilot the development of a drug product based on noribogaine and negotiate a definitive agreement for long-term collaboration. Nextage has granted MindMed an exclusive license to use all new data and study results from the collaboration. The collaboration has the potential to revolutionize brain and CNS treatment and develop life-changing treatments for patients.","partners":["Nextage Therapeutics"],"customers":null,"investors":null,"confidence":9,"key_topics":["MindMed","Nextage Therapeutics","psychedelic drug candidates","Brain Targeting Liposome System","delivery technology"],"date_of_event":"May 24, 2021","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"DoQERe0S3Jy78HLIEPQTsKIgjE6waxSVsH0jfJ8pPQc2ew8kh5wIIB","news_summary":"MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2d81dc89-b53c-47fb-89ed-c466189a98ce","date":"Dec 19, 2018","link":"https://en.globes.co.il/en/article-micromedic-jumps-entering-medical-cannabis-sector-1001265515","source":"en.globes.co.il","visible":1,"analysis":{"tags":"cannabis","company":"Micromedic Technologies Ltd.","layoffs":null,"summary":"Micromedic Technologies, a cancer testing company, has announced its intention to enter the cannabis industry. The companys share price rose by 10% following the announcement. Micromedic believes that its experience in plant extraction for its cancer testing could be relevant in the cannabis field. The company has not yet specified which part of the cannabis sector it wants to operate in, but it has had preliminary meetings with medical cannabis companies. Micromedic currently generates revenue from its CellDetect test and does not expect its entry into the cannabis field to impact its current cancer testing business. The company is considering raising capital but has not made a decision yet.","partners":"BioLight Life Sciences","customers":null,"investors":"BioLight Life Sciences","confidence":8,"key_topics":["medical companies","cannabis industry","plant extraction","CellDetect test","revenue"],"date_of_event":"December 19, 2018","valuation_amount":"NIS 13 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IIucZHnLgcgonvPKhnLXFZ2VxOFVvtPKA6VCQpGBVUVambJO7p2U10","news_summary":"Micromedic jumps on entering medical cannabis sector","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6d12056c-47e9-4237-aca1-06f62fcd5aa6","date":"Oct 14, 2018","link":"https://www.jpost.com/Israel-News/Israeli-cancer-diagnostic-company-secures-lucrative-China-distribution-deal-569372","source":"www.jpost.com","visible":1,"analysis":{"tags":"distribution deal","company":"Micromedic Technologies","layoffs":null,"summary":"Micromedic Technologies has signed an exclusive distribution deal in China for its bladder cancer detection platform. The deal with Shanghai Gensource Medical Appliances will distribute Micromedics product to customers in 25 cities across China and over 8,000 hospitals and medical centers. The minimum purchase requirement for diagnostic products is approximately NIS 500,000 by the end of 2019, increasing by 10% annually from 2020. Bladder cancer is the sixth most prevalent form of cancer among Chinese males, with 80,000 new cases diagnosed each year. Micromedic also recently announced a distribution deal with Italian pharmaceutical company Menarini Group.","partners":["Shanghai Gensource Medical Appliances","Menarini Group"],"customers":null,"investors":null,"confidence":8,"key_topics":["China","bladder cancer detection","distribution deal","Shanghai Gensource Medical Appliances","Micromedic CEO"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"b9fSgQwlYpOtKFF9rtkz0Uj5AQCleRO2ehfFpoeGGRcGCskxlXAA0A","news_summary":"https://www.jpost.com/Israel-News/Israeli-cancer-diagnostic-company-secures-lucrative-China-distribution-deal-569372","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0552ab95-9ec8-4ba8-a0b4-86f4871c9bd8","date":"Feb 27, 2018","link":"https://www.israel21c.org/israeli-breakthrough-in-noninvasive-prostate-cancer-test/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"medical technology","company":"Micromedic Technologies","layoffs":null,"summary":"Micromedic Technologies noninvasive diagnostic test, CellDetect, has successfully detected prostate cancer cells with high sensitivity, according to scientists at Kaplan Medical Center in Israel. The test demonstrated 91.3% sensitivity and 75% specificity in detecting prostate cancer cells in urine samples. CellDetect has previously been effective in diagnosing cervical and bladder cancer and is expected to be implemented for use in additional cancer detection indications. The results of the clinical study are significant in providing a reliable diagnostic tool for determining whether and when to perform a prostate biopsy. Micromedic Technologies aims to transform prostate cancer diagnostics by offering a noninvasive, accurate, and reliable test that could improve the healthcare system and result in cost savings.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["prostate cancer","diagnostic test","CellDetect","clinical study","reliable test"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"STYlqfwRicPBJXiwkBzpfCBM55nC5NUb4pSc34aIm5raaPy2c2qEYs","news_summary":"Israeli breakthrough in noninvasive prostate cancer test","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"719489da-8bef-40e5-865d-7bd563ce8d9a","date":"Oct 13, 2014","link":"http://news.nocamels.com/2014/10/13/micromedic-reports-successful-cervical-cancer-diagnosis-in-china/","source":"news.nocamels.com","visible":1,"analysis":{"tags":"cancer diagnostics","company":"Micromedic","layoffs":null,"summary":"Micromedic, an Israeli cancer diagnostics company, announced the successful trial of its product for detecting cervical cancer at the Beijing Military Hospital. The product effectively marked the cancer cells, improving the diagnostic process. However, Micromedics current distributor in China cannot handle the anticipated sales volume, prompting the company to explore other distribution options in the country. Micromedics product is in high demand in China and India, as it is the only effective diagnostic test available. Micromedic is a subsidiary of Bio-Light Israeli Life Science Investments, which owns 31 percent of the company.","partners":null,"customers":null,"investors":"Bio-Light Israeli Life Science Investments","confidence":9,"key_topics":["cervical cancer","trial","distribution","China","India"],"date_of_event":"October 13, 2014","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UjpiCf7og4A5GNFXOQdaOwLqF9urpo9HnDG7beBqHT4ivxqbqcfQjv","news_summary":"Micromedic Reports Successful Cervical Cancer Diagnosis In China","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cde4da53-42a6-455e-891d-b06d67eefb32","date":"Mar 27, 2012","link":"http://www.globes.co.il/en/article-1000736730","source":"www.globes.co.il","visible":1,"analysis":{"tags":"acquisition","company":"BioMarCare","layoffs":null,"summary":"Micromedic Technologies Ltd. has acquired 33% of BioMarCare Technologies Ltd. and has an option to invest an additional $1 million. BioMarCare is developing tumor biomarkers for cancer diagnostics. The cancer biomarker market is predicted to reach $9.5 billion by 2014. The acquisition is part of Micromedics cluster strategy for cancer diagnostics. Hadasit Bio Holdings Ltd. is the seller of the shares. Hadasit Bio has made progress with its portfolio by bringing in foreign pharma companies and strategic partners. The event occurred on March 27, 2012.","partners":null,"customers":null,"investors":"Micromedic Technologies Ltd.","confidence":9,"key_topics":["tumor biomarkers","cancer diagnostics","cluster strategy","market growth","portfolio progress"],"date_of_event":"2012-03-27","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$1 million","structured_issues":["Acquisition","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RhCZNx8OdycUkTkfnsBfvHtteW9yv2nyvn7uDVe8hPm8nRcZGRN7ZG","news_summary":"Micromedic buys 33% of tumor biomarker co BioMarCare for $1m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"edc47355-5f36-4995-b822-9a1dc824cc34","date":"Sep 25, 2011","link":"https://en.globes.co.il/en/article-1000685698","source":"en.globes.co.il","visible":1,"analysis":{"tags":"acquisition","company":"Micromedic","layoffs":null,"summary":"Micromedic transferred cancer diagnostic portfolio company Zetiq to Bio-Light in exchange for the stake. Bio-Light acquired 100% of Zetiq Technologies in exchange for 3.94 million shares, giving it the controlling interest in Micromedic. Micromedic also allotted options exercisable for the same number of shares. Bio-Light chairman Israel Makov will become chairman of Micromedic. The deal is expected to help Micromedic move forward and position itself in the industry. Zetiqs CellDetect technology is a technique for fast and precise identification of cancer cells.","partners":null,"customers":null,"investors":"Bio-Light","confidence":8,"key_topics":["Micromedic","Zetiq","Bio-Light","cancer diagnostics","portfolio company"],"date_of_event":"September 25, 2011","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"wLi6miehVQygJYBkcncyTdZse1ARjEOKjkfGL8GxjwTUFG9SCAbIDO","news_summary":"Bio-Light acquires 21% of Micromedic","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e2089fc6-2ce9-43e9-81a5-ee3e37e5b384","date":"Jan 28, 2009","link":"https://en.globes.co.il/en/article-1000420803","source":"en.globes.co.il","visible":1,"analysis":{"tags":"diabetes diagnostic kits","company":"Micro Rap","layoffs":null,"summary":"Micro Rap, a portfolio company of Micromedic Technologies Ltd., has successfully completed a trial for its diagnostic kit for type-1 diabetes. The kit was able to identify 83.3% of patients and will now apply for marketing permits in Europe and the US. Micromedic purchased the commercial rights to the diabetes biomarker from BioRap Technologies Ltd. Micromedic owns 85% of Micro Rap, and BioRap owns 15%.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["diabetes diagnostic kits","trial results","marketing permits","technology transfer","ownership"],"date_of_event":"January 28, 2009","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"32BlZ2YmfHHuCmzAL0FXfuh1vk23kyYDDw3Xm6HwzBoFzMiXNFBI6D","news_summary":"Micromedic unit posts positive diabetes test result","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":14,"techcommunityinvolvement":null,"mediagallery":[{"id":"Bh7lzpaUDPuaJ5E7p4kbyzLypm5gaPO6bITVWq1MzZmr0QtNvqsqJF","timestamp":"2022-10-21 13:43:30.000000","resources_type":2,"resources_title":"","resources_file_name":"6rtNobYcEVA","alt":"","imageurl":"https://img.youtube.com/vi/6rtNobYcEVA/0.jpg","url":"http://youtu.be/6rtNobYcEVA"}],"tags":["pharmaceuticals","drug-development"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kfr0LkJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz8d0LDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"R&D","products":[],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":7257424,"marketcapitaldate":"2025-02-01T14:01:00.000Z","funding":{"investors":0,"lastfunding":"Undisclosed","totalrounds":1,"fundingstage":"Public","totalfunding":"Undisclosed","publicinvestors":0,"lastpublicfunding":0,"totalpublicrounds":1,"totalpublicfunding":0},"team":[{"name":"Ilan  Avni","email":"Ilan@nextar.co.il","phone":"0523667750","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Ju1ipkJDA","bounced":false,"claimed":1,"founder":0,"urlname":"ilan-avni-2","visible":1,"memberid":"PADekeTpSZTc9sziNdNYmMod2YNND4IWHnY7QV86HbtgsMXn1lNqu0","position":"CEO","last_name":"Avni","claimtoken":"5QVCAByy3iBNTVtvteKvtuTr4yOrK5UE9dqutbEB7uVCikTPqZWqzK","first_name":"Ilan ","picturekey":null,"claimeddate":"2026-03-02","linkedinurl":"https://www.linkedin.com/in/ilanavni/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2026-03-02 13:55:43.000000","initials":"IA","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverifydate":"2020-04-30T00:00:00.000Z","crunchbaseid":"micromedic","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":null,"creator_email":null,"createdate":"2014-10-14T00:00:00.000Z","biverification":"Sharon Shapira","sectorverification":null,"affiliatedOrganizations":[{"id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIL7p4gKDA","name":"Nextar Chempharma Solutions","type":"Startup","hidden":false,"fullurl":"/company_page/nextar-chempharma-solutions","logokey":"$2Vo4yurr9BDq5p7ijHGEXNEkRzBLU3nhZ51zAjxyNIgbF2840MCz3u","logourl":"https://storage.googleapis.com/clean-finder-353810/$2Vo4yurr9BDq5p7ijHGEXNEkRzBLU3nhZ51zAjxyNIgbF2840MCz3u","onClick":"","visibilityClassName":"","visibilityTooltip":""},{"id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4IKZgPUJDA","name":"Nextage Innovation","type":"Corporate Accelerator","hidden":false,"fullurl":"/program_page/nextage-innovation","logokey":"$cEdRmDPYS7Y1kxPqSk1d52UU7UB8Me6MfyO9rUKHcwBwu87zp30GSu","logourl":"https://storage.googleapis.com/clean-finder-353810/$cEdRmDPYS7Y1kxPqSk1d52UU7UB8Me6MfyO9rUKHcwBwu87zp30GSu","onClick":"","visibilityClassName":"","visibilityTooltip":""}],"timeline":[{"id":"oQIbhr5jIL2zX0OtctoMNdxBLBnwh4el6NuXkPDPYtVUbaEKtgzE4W","date":"Mar 2025","amount":"Undisclosed","source":"","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"acquiredcompany_mna":"Nextar Chempharma Solutions","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIL7p4gKDA","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/company_page/nextar-chempharma-solutions","acquiredcompany_mna_logokey":"$2Vo4yurr9BDq5p7ijHGEXNEkRzBLU3nhZ51zAjxyNIgbF2840MCz3u","acquiredcompany_mna_urlname":"/company_page/nextar-chempharma-solutions","acquiredcompany_mna_homepage":"https://www.nextar.co.il","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$2Vo4yurr9BDq5p7ijHGEXNEkRzBLU3nhZ51zAjxyNIgbF2840MCz3u","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCvksLeCgw","date":"May 2021","amount":"Undisclosed","source":"https://maya.tase.co.il/reports/details/1373431/2/0","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Nextage Innovation","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4IKZgPUJDA","acquiredcompany_mna_type":"Corporate Accelerator","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/program_page/nextage-innovation","acquiredcompany_mna_logokey":"$cEdRmDPYS7Y1kxPqSk1d52UU7UB8Me6MfyO9rUKHcwBwu87zp30GSu","acquiredcompany_mna_urlname":"/program_page/nextage-innovation","acquiredcompany_mna_homepage":"https://nextageinnovation.com","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$cEdRmDPYS7Y1kxPqSk1d52UU7UB8Me6MfyO9rUKHcwBwu87zp30GSu","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODIkNi1Cgw","date":"May 1993","amount":"Undisclosed","source":"https://info.tase.co.il/Eng/General/Company/Pages/companyMainData.aspx?companyID=000433&","ticker":"NXTG","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"TASE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCot526Cgw","stockexchange_logokey":"$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"3/2006","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Nextage Therapeutics","logourl":"https://storage.googleapis.com/clean-finder-353810/$6gCLHFXDFnKOcxSO98mGVlyq7Fm0EYizrAe5OnYzcblGQEetk80kys.png","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$6gCLHFXDFnKOcxSO98mGVlyq7Fm0EYizrAe5OnYzcblGQEetk80kys.png","seoabout":"Nextage Therapeutics (TASE: NXTG) is a pioneer in targeted nano-liposomes based drug delivery across the blood-brain-barrier. The company has developed a p...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":1,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"},{"depth":3,"name":"Cosmetic Materials","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kfr0LkJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Medical Devices Industry","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz8d0LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA>Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Cosmetic Materials#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kfr0LkJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Medical Devices Industry#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz8d0LDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Medical Devices#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA/Medical Treatment & Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drug Delivery#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Cosmetic Materials#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kfr0LkJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Medical Devices Industry#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz8d0LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Molecules#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Medical Devices","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices","children":[{"title":"Medical Treatment & Therapeutics","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Medical Devices>Medical Treatment & Therapeutics"}]},{"title":"Pharma & Medical Biotechnology","key":"0-0-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drug Delivery","key":"0-0-1-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drug Delivery"},{"title":"Cosmetic Materials","key":"0-0-1-1","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Cosmetic Materials"},{"title":"Drugs Discovery & Development","key":"0-0-1-2","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]},{"title":"Medical Devices Industry","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Medical Devices Industry"}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Molecules","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Molecules"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Medical Devices","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8ivUIDA","classificationName":"sectorclassification"},{"depth":3,"name":"Medical Treatment & Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfQhvYKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drug Delivery","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1r_gKDA","classificationName":"sectorclassification"},{"depth":3,"name":"Cosmetic Materials","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kfr0LkJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Molecules","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz7ewLDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Medical Devices Industry","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Jvz8d0LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Medical Devices","Medical Treatment & Therapeutics","Pharma & Medical Biotechnology","Drug Delivery","Cosmetic Materials","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Molecules"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals","Medical Devices Industry"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODIkNi1Cgw","date":"May 1993","amount":"Undisclosed","source":"https://info.tase.co.il/Eng/General/Company/Pages/companyMainData.aspx?companyID=000433&","ticker":"NXTG","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"TASE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCot526Cgw","stockexchange_logokey":"$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null}],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[{"id":"oQIbhr5jIL2zX0OtctoMNdxBLBnwh4el6NuXkPDPYtVUbaEKtgzE4W","date":"Mar 2025","amount":"Undisclosed","source":"","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"acquiredcompany_mna":"Nextar Chempharma Solutions","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIL7p4gKDA","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/company_page/nextar-chempharma-solutions","acquiredcompany_mna_logokey":"$2Vo4yurr9BDq5p7ijHGEXNEkRzBLU3nhZ51zAjxyNIgbF2840MCz3u","acquiredcompany_mna_urlname":"/company_page/nextar-chempharma-solutions","acquiredcompany_mna_homepage":"https://www.nextar.co.il","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$2Vo4yurr9BDq5p7ijHGEXNEkRzBLU3nhZ51zAjxyNIgbF2840MCz3u","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCvksLeCgw","date":"May 2021","amount":"Undisclosed","source":"https://maya.tase.co.il/reports/details/1373431/2/0","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Nextage Innovation","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4IKZgPUJDA","acquiredcompany_mna_type":"Corporate Accelerator","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/program_page/nextage-innovation","acquiredcompany_mna_logokey":"$cEdRmDPYS7Y1kxPqSk1d52UU7UB8Me6MfyO9rUKHcwBwu87zp30GSu","acquiredcompany_mna_urlname":"/program_page/nextage-innovation","acquiredcompany_mna_homepage":"https://nextageinnovation.com","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$cEdRmDPYS7Y1kxPqSk1d52UU7UB8Me6MfyO9rUKHcwBwu87zp30GSu","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"others":[]}}